The gastric cancer diagnostic market was valued at $2.3 billion in 2022 and is estimated to reach $3.8 million by 2032, exhibiting a CAGR of 5.3% from 2023 to 2032. Gastric cancer diagnostic refers to the process of identifying and confirming the presence of gastric (stomach) cancer in an individual. It involves various medical procedures and tests aimed at detecting and diagnosing this type of cancer. The goal of gastric cancer diagnostics is to determine if a person has malignant (cancerous) growth in the stomach, understand its characteristics, including the type and stage of the cancer, and provide valuable information to guide treatment decisions. Gastric cancer has become the second leading cause of cancer-related deaths worldwide, and its epidemiology has undergone significant changes in recent decades. During endoscopy or surgery, a tissue sample (biopsy) is collected from the suspicious area in the stomach. The biopsy is then examined by a pathologist to confirm the presence of cancer and determine its type and grade.
The gastric cancer diagnostic market has experienced significant growth owing to rise in prevalence of gastric cancer and advancements in diagnostics technology. For instance, according to the National Library of Medicine, a total of 1,089,103 new stomach cancer cases were reported globally for 2020. In addition, rise in awareness, screening programs about the importance of stomach cancer screening and the implementation of organized screening programs in some regions lead to early detection and diagnosis of gastric cancer, which fuels the market growth.
Furthermore, the rise in trend toward personalized or precision medicine fosters the use of molecular and genetic testing to identify specific genetic markers and tailor treatments to individual patients, boosting the demand for diagnostic tests and propelling the market growth. Furthermore, the ongoing advancements in diagnostic tools and technologies, such as improved endoscopy, molecular & genetic testing, and imaging techniques, enhance the accuracy and early detection of gastric cancer, which is expected to drive the market growth.
The gastric cancer diagnostic market is segmented into product, disease type, end user, and region. By product, the market is segregated into reagents & consumables and instruments. By disease type, the market is categorized into adenocarcinoma, gastric lymphoma, and others. By end user, the market is classified into hospitals, diagnostic laboratories, and diagnostic imaging centers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major key players that operate in the gastric cancer diagnostic market are Bio-Rad Laboratories, Inc., Qiagen NV., Agilent Technologies, Inc., Exact Sciences Corporation, MiRXES Pte Ltd, Hipro Biotechnology Co.,Ltd., Fulgent Genetics, Endofotonics Pte Ltd, Abbott Laboratories, and F. Hoffmann-La Roche Ltd. Key players have adopted product approval, partnership, and agreement as key developmental strategies to improve the product portfolio of the gastric cancer diagnostic market.
The gastric cancer diagnostic market has experienced significant growth owing to rise in prevalence of gastric cancer and advancements in diagnostics technology. For instance, according to the National Library of Medicine, a total of 1,089,103 new stomach cancer cases were reported globally for 2020. In addition, rise in awareness, screening programs about the importance of stomach cancer screening and the implementation of organized screening programs in some regions lead to early detection and diagnosis of gastric cancer, which fuels the market growth.
Furthermore, the rise in trend toward personalized or precision medicine fosters the use of molecular and genetic testing to identify specific genetic markers and tailor treatments to individual patients, boosting the demand for diagnostic tests and propelling the market growth. Furthermore, the ongoing advancements in diagnostic tools and technologies, such as improved endoscopy, molecular & genetic testing, and imaging techniques, enhance the accuracy and early detection of gastric cancer, which is expected to drive the market growth.
The gastric cancer diagnostic market is segmented into product, disease type, end user, and region. By product, the market is segregated into reagents & consumables and instruments. By disease type, the market is categorized into adenocarcinoma, gastric lymphoma, and others. By end user, the market is classified into hospitals, diagnostic laboratories, and diagnostic imaging centers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major key players that operate in the gastric cancer diagnostic market are Bio-Rad Laboratories, Inc., Qiagen NV., Agilent Technologies, Inc., Exact Sciences Corporation, MiRXES Pte Ltd, Hipro Biotechnology Co.,Ltd., Fulgent Genetics, Endofotonics Pte Ltd, Abbott Laboratories, and F. Hoffmann-La Roche Ltd. Key players have adopted product approval, partnership, and agreement as key developmental strategies to improve the product portfolio of the gastric cancer diagnostic market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastric cancer diagnostic market analysis from 2022 to 2032 to identify the prevailing gastric cancer diagnostic market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the gastric cancer diagnostic market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global gastric cancer diagnostic market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product
- Reagents and Consumables
- Instruments
By Disease Type
- Adenocarcinoma
- Gastric Lymphoma
- Others
By End User
- Hospitals
- Diagnostic Laboratories
- Diagnostic Imaging Centers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Exact Sciences Corporation
- Fulgent Genetics
- Endofotonics Pte Ltd
- MiRXES Pte Ltd
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Hipro Biotechnology Co.,Ltd.
- Abbott Laboratories
- Qiagen NV.
- Bio-Rad Laboratories, Inc.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT
CHAPTER 5: GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE
CHAPTER 6: GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER
CHAPTER 7: GASTRIC CANCER DIAGNOSTIC MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, the gastric cancer diagnostic market was valued at $2.3 billion in 2022, and is estimated to reach $3.8 billion by 2032, growing at a CAGR of 5.3% from 2023 to 2032. The Gastric Cancer Diagnostic Market is likely to experience a significant growth rate of 5.3% from 2023-2032 owing to increase in demand for gastric cancer diagnostic products from medical device and supplies sector.Gastric cancer diagnostics includes a range of methods, including clinical assessments, endoscopic procedures, imaging studies, blood tests, molecular & genetic testing, and histopathology. The results of these diagnostic tests help determine the extent and nature of the disease, enabling healthcare professionals to design appropriate treatment plans for patients with gastric cancer. Key factors driving the growth of the gastric cancer diagnostic market include the rise in prevalence of gastric cancer. For instance, according to the American Society of Clinical Oncology (ASCO), in 2023, estimated that around 26,500 (15,930 men and 10,570 women) in the U.S. is expected to be diagnosed with stomach cancer. In addition, from the same source, worldwide around 1,089,103 people were diagnosed with stomach cancer in 2020. This growing prevalence of gastric cancer is driving the demand for gastric cancer diagnostic tests which propels the market growth.
In addition, advanced diagnostic technologies offer increased accuracy in identifying gastric cancer. This means they detect smaller and earlier-stage tumors that have been missed with older methods. Early detection often leads to better treatment outcomes and increased survival rates. The development of new diagnostic technologies, such as biomarker testing and circulating tumor DNA tests, is driving the growth of the gastric cancer diagnostic market. These tests help detect gastric cancer at an early stage, which improves patient outcomes.
Furthermore, growing public awareness about the importance of regular check-ups, cancer screenings, and early diagnosis is driving more individuals to seek gastric cancer diagnostic services, leading to earlier detection. Several governments in the region have implemented cancer screening and prevention programs, providing access to affordable or subsidized diagnostic services, further encouraging early diagnosis. Moreover, the surge in awareness about gastric cancer is a significant driver for the gastric cancer diagnostic market. Increased public awareness leads to more individuals seeking information, understanding the importance of early detection, and proactively seeking diagnostic tests. The increase in awareness about gastric cancer and its risk factors is driving the demand for diagnostic tests and boosting the market growth.
The market also offers growth opportunities to the key players in the market. The gastric cancer diagnostic market remains attractive as it is a large and growing clinical area with a rise in incidences of cancer cases, globally. Therefore, significant unmet need exists due to the rise in need for more compelling clinical evidence and improved patient convenience which provide the opportunity to market growth. One of the most significant unmet needs in cancer diagnosis is the early detection of gastric cancer, especially in its pre-symptomatic stages. Development of highly sensitive and specific diagnostic tools that detect cancer at an earlier point have led to more successful treatment outcomes.
The gastric cancer diagnostic market is segmented into product, disease type, end user, and region. On the basis of product, the market is categorized into reagents & consumables, and instruments. By disease type, the market is classified into adenocarcinoma, gastric lymphoma, and others. On the basis of end user, it is segregated into hospitals, diagnostic laboratories, and diagnostic imaging centers. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific ((Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Bio-Rad Laboratories, Inc., Qiagen NV., Agilent Technologies, Inc., Exact Sciences Corporation, MiRXES Pte Ltd, Hipro Biotechnology Co.,Ltd., Fulgent Genetics, Endofotonics Pte Ltd, Abbott Laboratories, and F. Hoffmann-La Roche Ltd. The players in the market have been actively engaged in the adoption of various strategies such as product approval, partnership, and agreement to remain competitive and gain an advantage over the competitors in the market. For instance, in October 2021, Agilent Technologies Inc. announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.
Key Market Insights
By product, the reagents and consumables segment was the largest revenue contributor to the market and is estimated to reach $2.4 billion by 2032. However, the instruments segment is anticipated to grow at the highest CAGR of 5.6% during the forecast period.By disease type, adenocarcinoma segment dominated the global market with a highest CAGR of 5.7% during the forecast period.
Based on end user, the diagnostic laboratories segment was the largest revenue contributor to the market with a highest CAGR of 6.0% during the forecast period.
Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Exact Sciences Corporation
- Fulgent Genetics
- Endofotonics Pte Ltd
- MiRXES Pte Ltd
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Hipro Biotechnology Co.,Ltd.
- Abbott Laboratories
- Qiagen NV.
- Bio-Rad Laboratories, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
